NVCR N Stock Overview
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NovoCure Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$275.39 |
| 52 Week High | US$2,140.47 |
| 52 Week Low | US$275.39 |
| Beta | 0.52 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| NVCR N | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how NVCR N performed against the MX Medical Equipment industry.
Return vs Market: Insufficient data to determine how NVCR N performed against the MX Market.
Price Volatility
| NVCR N volatility | |
|---|---|
| NVCR N Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: NVCR N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NVCR N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,320 | Asaf Danziger | www.novocure.com |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited Fundamentals Summary
| NVCR N fundamental statistics | |
|---|---|
| Market cap | Mex$27.09b |
| Earnings (TTM) | -Mex$3.35b |
| Revenue (TTM) | Mex$8.56b |
3.2x
P/S Ratio-8.1x
P/E RatioIs NVCR N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVCR N income statement (TTM) | |
|---|---|
| Revenue | US$503.98m |
| Cost of Revenue | US$124.00m |
| Gross Profit | US$379.98m |
| Other Expenses | US$577.25m |
| Earnings | -US$197.27m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.85 |
| Gross Margin | 75.40% |
| Net Profit Margin | -39.14% |
| Debt/Equity Ratio | 144.3% |
How did NVCR N perform over the long term?
See historical performance and comparison